Epcoritamab is a bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. Epcoritamab is an IgG1-bispecific antibody that simultaneously binds to CD3 on T-cells and CD20 on B-cells.
- Mechanism
- Curator reviewed · 2 references
Epcoritamab is a humanized bispecific IgG1 antibody that targets CD20 on B-cells and CD3 on T-cells. Unlike other monoclonal antibodies that target a single receptor on the surface of lymphocytes, epcoritamab can recognize and bind two different targets, the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and healthy B-lineage cells. By targeting both receptors, epcoritamab promotes the release of proinflammatory cytokines and the lysis of CD20+ malignant B-cells through selective T-cell–mediated cytotoxic activity.
- Primary indication
- Epcoritamab is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade...Curator reviewed · 6 structured indications
- Formula / weight
- C6471H9999N1735O2007S44 · 149000.0 Da (approximate)
- First approval
- Canada, 2023 · United States, 2023 · European Union, 2023
- Also known as
- Epcoritamab-bysp
- Code names
- ABBV-GMAB-3013 · GEN-3013
- Brand names
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Epcoritamab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account